2012 Advisory Board Members are inclusive of:
Translating Toxicological Observation into Prediction Technology
The current cost of discovering and developing a drug is approximately $900 million, resulting in continually growing pressure to avoid late stage drug attrition and its associated costs. The failure rate of drugs that pass animal testing and are entered into clinical trials is more than 90 percent. There is also an incidence of drugs that pass through clinical trials on humans and go on to be distributed into the marketplace prior to the discovery of adverse effects (toxicity). Pharmaceutical companies stand to save billions of dollars by replacing detection technology with prediction technology.
IQPC’s 1st North American Predictive Toxicology Summit will discuss and develop techniques that will provide guidance on the right balance between mitigation and management of safety risk and enable companies to significantly improve the predictive value of their preclinical safety assessment resulting in decreased safety-related attrition rate in clinical trials.
At this platform, uniquely designed for drug and nutrition developers, you will benefit from exposure to the latest breakthroughs in toxicity prediction during 3 days of in-depth discussions and interactive workshops.
Scientists are still challenged in reducing late stage drug attrition and better understanding a drug candidate’s liability during early development phases, this forum, the Predictive Toxicology Summit, will provide you with strategies for:
- Measuring the impact of early risk assessment
- Achieving the right balance for mitigation and management of safety risk
- Evaluating the predictive value of available tests, assays and tools
- Decreasing safety-related attrition rate in clinical trials
IQPC’s Inaugural North American Predictive Toxicology Summit is your best tool available in 2012 for reduced attrition, enhanced efficacy screening, and increased exposure to the latest models, tools and technologies in predictive toxicology.
“This event offers a timely platform to the North American pharmaceutical market that will enable companies to save time and money through enhanced toxicity prediction.”- Matthew Peters, PhD, Principal Scientist, Astra Zeneca
“This event will offer the opportunity for toxicology professionals to share state-of-the-art ideas in a dedicated forum.”- Yvonne Will, PhD, Senior Principal Scientist, Compound Safety Prediction, Pfizer